Teacher Retirement System of Texas Increases Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Teacher Retirement System of Texas increased its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 26.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,609 shares of the company’s stock after buying an additional 3,674 shares during the period. Teacher Retirement System of Texas’ holdings in SpringWorks Therapeutics were worth $636,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the company. Principal Financial Group Inc. lifted its stake in SpringWorks Therapeutics by 102.5% in the third quarter. Principal Financial Group Inc. now owns 918,445 shares of the company’s stock worth $29,427,000 after acquiring an additional 464,903 shares during the period. Raymond James Financial Inc. acquired a new stake in SpringWorks Therapeutics during the 4th quarter worth about $10,527,000. Walleye Capital LLC boosted its position in SpringWorks Therapeutics by 2,439.4% in the third quarter. Walleye Capital LLC now owns 286,093 shares of the company’s stock valued at $9,166,000 after buying an additional 274,827 shares during the last quarter. Soros Fund Management LLC boosted its holdings in shares of SpringWorks Therapeutics by 45.3% in the 3rd quarter. Soros Fund Management LLC now owns 559,321 shares of the company’s stock valued at $17,921,000 after acquiring an additional 174,321 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in SpringWorks Therapeutics by 131.4% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 285,555 shares of the company’s stock worth $9,149,000 after purchasing an additional 162,137 shares during the period.

SpringWorks Therapeutics Stock Down 0.2 %

NASDAQ:SWTX opened at $47.41 on Monday. The stock’s fifty day moving average is $47.98 and its two-hundred day moving average is $39.75. SpringWorks Therapeutics, Inc. has a 52 week low of $28.21 and a 52 week high of $62.00. The stock has a market capitalization of $3.55 billion, a price-to-earnings ratio of -13.62 and a beta of 0.76.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. The company had revenue of $61.55 million during the quarter, compared to analyst estimates of $60.53 million. On average, sell-side analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current fiscal year.

Insider Activity

In other news, Director Daniel Lynch sold 175,000 shares of SpringWorks Therapeutics stock in a transaction on Monday, February 10th. The shares were sold at an average price of $54.46, for a total value of $9,530,500.00. Following the transaction, the director now directly owns 130,944 shares of the company’s stock, valued at $7,131,210.24. The trade was a 57.20 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Bhavesh Ashar sold 1,016 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $61.19, for a total transaction of $62,169.04. Following the sale, the insider now owns 62,053 shares of the company’s stock, valued at $3,797,023.07. This trade represents a 1.61 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 440,766 shares of company stock worth $24,402,956. 7.61% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SWTX. Evercore ISI lifted their target price on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Wedbush restated an “outperform” rating and issued a $81.00 price objective on shares of SpringWorks Therapeutics in a report on Thursday, February 20th. Guggenheim lowered their target price on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $74.00 target price on shares of SpringWorks Therapeutics in a report on Friday, February 21st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, SpringWorks Therapeutics has an average rating of “Buy” and an average target price of $73.20.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.